Navigation Links
BioTech Holdings Identifies and Files Patent on ProCell Mechanism of Action in Saving Limbs from Amputation
Date:10/9/2017

SAN DIEGO, Oct. 9, 2017 /PRNewswire/ -- BioTech Holdings announced today identification and patenting of a biological mechanism by which its ProCell stem cell therapy prevents limb loss in animal models of critical limb ischemia.  The Company, demonstrated that treatment with ProCell resulted in more than double the amount of limbs saved as compared to standard bone marrow stem cell administration.  Interestingly, neutralization of the molecule HGF resulted in reduction of therapeutic effect. 

Critical limb ischemia is a condition, primarily in diabetics, that causes 250,000 amputations per year in the USA.  At present there is no medical treatment for this condition and surgical approaches are applicable to less than half of patients.

ProCell is a personalized stem cell therapy using the an FDA approved peptide hormone to stimulate new blood vessel production in patients whose tissues lack oxygen, a condition termed "ischemia." In addition to critical limb ischemia, lack of oxygen is associated with heart failure and stroke.

"The identification of HGF-1 as a mechanism by which ProCell mediates its therapeutic effects is a major step forward in our developmental path towards FDA IND filing," said Thomas Ichim, Ph.D, President and CEO of BioTech Holdings. "We are aggressively filing intellectual property on this useful biomarker, which will assist us in optimizing doses as we enter formal clinical trials in the USA."

BioTech Holdings previously reported efficacy signals in a pilot study of critical limb ischemia patients.  The Company plans to file its Investigational New Drug application with the FDA before year end.

Contacts

Thomas E Ichim, Ph.D
President and Chief Executive Officer
BioTech Holdings
9255 Towne Centre Drive, #450
San Diego, CA 92121
179878@email4pr.com
858 353 4303
Twitter: @biotechholdings

 

View original content with multimedia:http://www.prnewswire.com/news-releases/biotech-holdings-identifies-and-files-patent-on-procell-mechanism-of-action-in-saving-limbs-from-amputation-300533444.html


'/>"/>
SOURCE BioTech Holdings
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Arzeda and TeselaGen Partner to Advance Biodesign Technologies for Industrial Biotechnology
2. FierceBiotech Reveals the Fierce 15 Winners of 2017
3. DrugDev to Promote Adoption of Innovative Technologies to Advance Clinical Study Efficiency at Prestigious Pharma and Biotech Industry Conferences in Q4
4. Pharma, Biotech Clinical Trial Leaders to Convene for 3rd Annual DrugDev Summit to Promote Collaboration, Technology Innovation, Engaged Sites, and More Informed Patients
5. PRC Clinical Partners With SDC to Expand ClinPulse Event Series to the Boston Biotech Hub
6. Demand for DrugDev Spark™ Soars Among Small Biotechs and Pharma Seeking Best-in-Class Technology for Clinical Trial Planning, Startup and Conduct
7. Biotech Pioneer BIOLIFE4D Submits Regulation A+ Filing with SEC for up to $50 Million Initial Public Offering
8. Lifecycle Biotechnologies Announces Promotion of Ashley Wilhelm to Customer Outcomes Manager
9. The Art of Science Inspires Residency Program at Biotech Company
10. Lesaffre Invests in Intralytix, a US Biotechnology Company
11. Panitch Schwarze Life Sciences Practice Leader Speaks at Biotechnology Conference in Shanghai
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced that ... SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 ... cross the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
(Date:10/10/2017)... ... 2017 , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on ... DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
Breaking Biology Technology:
(Date:6/23/2017)... and ITHACA, N.Y. , June 23, ... University, a leader in dairy research, today announced a ... to help reduce the chances that the global milk ... of this dairy project, Cornell University has become the ... the Food Supply Chain, a food safety initiative that ...
(Date:5/23/2017)... -- Hunova, the first robotic gym for the rehabilitation and functional motor sense ... Genoa, Italy . The first 30 robots will be available ... USA . The technology was developed and patented at the IIT ... Movendo Technology thanks to a 10 million euro investment from entrepreneur Sergio ... ...
(Date:5/16/2017)... May 16, 2017   Bridge Patient Portal ... and MD EMR Systems , an electronic ... for GE, have established a partnership to build ... and the GE Centricity™ products, including Centricity Practice ... These new integrations will allow healthcare ...
Breaking Biology News(10 mins):